Emanuela Ottaviani

Istituto di Ematologia di Bologna — Italy

Medicine · Health Sciences

35h-index4.9kcitations374works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(173), Chronic Myeloid Leukemia Treatments(129), Acute Lymphoblastic Leukemia research(98), Chronic Lymphocytic Leukemia Research(83), Myeloproliferative Neoplasms: Diagnosis and Treatment(61)

Publications374 total

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial
Blood·2025Open Access
An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience
International Journal of Molecular Sciences·2025Open Access
Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
International Journal of Molecular Sciences·2025· 1 citedOpen Access
Upfront intensive treatment analysis of the Italian Cohort Study on <i>FLT3</i>‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
Cancer·2025Open Access
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction
International Journal of Molecular Sciences·2025Open Access
T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia
Blood·2024Open Access
Venetoclax and Azacitidine for Relapse Prevention in <i>NPM1</i>-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
Blood·2024· 2 citedOpen Access
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets
International Journal of Molecular Sciences·2024· 4 citedOpen Access
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
Annals of Hematology·2024· 5 citedOpen Access
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells
Frontiers in Immunology·2024· 8 citedOpen Access
Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomes
2024Open Access
T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in <i>FLT3</i>-Mutated Acute Myeloid Leukemia
Blood·2023· 1 cited
Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients
Blood·2023
PB1981: EXPERIENCE OF FOUR LABORATORIES OF THE ITALIAN CML LABNET NETWORK IN THE USE OF THE CEPHEID CARTRIDGE SYSTEM
HemaSphere·2023Open Access
PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
HemaSphere·2023Open Access
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
Cells·2023· 17 citedOpen Access
A venetoclax and azacitidine <scp>bridge‐to‐transplant</scp> strategy for <i>NPM1</i>‐<scp>mutated</scp> acute myeloid leukaemia in molecular failure
British Journal of Haematology·2023· 24 citedOpen Access
Supplementary Data from Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells
2023Open Access
Supplementary Data from Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells
2023Open Access
Supplementary Methods, Tables 1-7, Figures 1-4 from &lt;i&gt;CDKN2A/B&lt;/i&gt; Alterations Impair Prognosis in Adult &lt;i&gt;BCR-ABL1&lt;/i&gt;–Positive Acute Lymphoblastic Leukemia Patients
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Giovanni Martinelli(39), Michele Baccarani(26), Nicoletta Testoni(22), Ilaria Iacobucci(16), Cristina Papayannidis(14), Simona Soverini(13), S Tura(13), Giuseppe Visani(12), Giuseppe Saglio(11), Anna Ferrari(11), Annalisa Lonetti(10), Fabrizio Pane(10), Michèle Cavo(10), Pier Paolo Piccaluga(9), Stefania Paolini(9), Marilina Amabile(9), Daniela Cilloni(8), Carolina Terragna(8), Patrizia Tosi(8), Antonio De Vivo(8)